Outlook Therapeutics is trading at $1.58 (5.65% down) as the stock experiences a pullback following a sharp multi-day run-up.
- The recent rally was fueled by growing investor attention on the July 29, 2026, FDA PDUFA action date for LYTENAVA following its BLA resubmission and acceptance.
- With no fresh company-specific news today, the move appears to be driven by short-term volatility and profit-taking as traders reposition ahead of the upcoming regulatory catalyst.